Vinay Prasad, FDA’s Director of the Center for Biologics Evaluation and Research. PHOTO: FDA.GOV The nation’s controversial top vaccine...
Vous n'êtes pas connecté
Maroc - The New York Times - NYTimes.com Home Page (U.S.) - 05/Mar 10:01
Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors are closing on their options.
Vinay Prasad, FDA’s Director of the Center for Biologics Evaluation and Research. PHOTO: FDA.GOV The nation’s controversial top vaccine...
Vinay Prasad, FDA’s Director of the Center for Biologics Evaluation and Research. PHOTO: FDA.GOV The nation’s controversial top vaccine...
The Trump administration’s head of vaccines will leave the U.S. Food and Drug Administration next month following a tenure marked by several...
The commentary titled ‘Establishing a Commercial Solution for Extremely Rare Genetic Diseases’ was published in Nature Biotechnology Commentary...
The commentary titled ‘Establishing a Commercial Solution for Extremely Rare Genetic Diseases’ was published in Nature Biotechnology Commentary...
Kim Jong Un voted in the election for North Korea’s rubber-stamp parliament on Sunday, according to state media, casting his ballot at a coal mine...
Kim Jong Un voted in the election for North Korea’s rubber-stamp parliament on Sunday, according to state media, casting his ballot at a coal mine...
Dr. Vinay Prasad drew criticism for overriding career scientists and rejecting drugs by companies seeking agency approval.
For years, elective medical treatment was often seen as something people arranged close to home. Today, that is changing. Across Europe, patients are...
For years, elective medical treatment was often seen as something people arranged close to home. Today, that is changing. Across Europe, patients are...